An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies
As technologies evolve, and diagnostics move from detection of single biomarkers toward complex signatures, an increase in the clinical use and regulatory submission of complex signatures is anticipated. However, to date, no complex signatures have been approved as companion diagnostics. In this art...
Saved in:
| Published in | Clinical cancer research Vol. 23; no. 6; pp. 1368 - 1372 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
American Association for Cancer Research Inc
15.03.2017
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1078-0432 1557-3265 1557-3265 |
| DOI | 10.1158/1078-0432.CCR-16-1098 |
Cover
| Abstract | As technologies evolve, and diagnostics move from detection of single biomarkers toward complex signatures, an increase in the clinical use and regulatory submission of complex signatures is anticipated. However, to date, no complex signatures have been approved as companion diagnostics. In this article, we will describe the potential benefit of complex signatures and their unique regulatory challenges, including analytic performance validation, complex signature simulation, and clinical performance evaluation. We also will review the potential regulatory pathways for clearance, approval, or acceptance of complex signatures by the FDA. These regulatory pathways include regulations applicable to in vitro diagnostic devices, including companion diagnostic devices, the potential for labeling as a complementary diagnostic, and the biomarker qualification program. Clin Cancer Res; 23(6); 1368–72. ©2016 AACR. |
|---|---|
| AbstractList | As technologies evolve, and diagnostics move from detection of single biomarkers toward complex signatures, an increase in the clinical use and regulatory submission of complex signatures is anticipated. However, to date, no complex signatures have been approved as companion diagnostics. In this article, we will describe the potential benefit of complex signatures and their unique regulatory challenges, including analytic performance validation, complex signature simulation, and clinical performance evaluation. We also will review the potential regulatory pathways for clearance, approval, or acceptance of complex signatures by the FDA. These regulatory pathways include regulations applicable to in vitro diagnostic devices, including companion diagnostic devices, the potential for labeling as a complementary diagnostic, and the biomarker qualification program. Clin Cancer Res; 23(6); 1368-72. ©2016 AACR.As technologies evolve, and diagnostics move from detection of single biomarkers toward complex signatures, an increase in the clinical use and regulatory submission of complex signatures is anticipated. However, to date, no complex signatures have been approved as companion diagnostics. In this article, we will describe the potential benefit of complex signatures and their unique regulatory challenges, including analytic performance validation, complex signature simulation, and clinical performance evaluation. We also will review the potential regulatory pathways for clearance, approval, or acceptance of complex signatures by the FDA. These regulatory pathways include regulations applicable to in vitro diagnostic devices, including companion diagnostic devices, the potential for labeling as a complementary diagnostic, and the biomarker qualification program. Clin Cancer Res; 23(6); 1368-72. ©2016 AACR. As technologies evolve, and diagnostics move from detection of single biomarkers toward complex signatures, an increase in the clinical use and regulatory submission of complex signatures is anticipated. However, to date, no complex signatures have been approved as companion diagnostics. In this article, we will describe the potential benefit of complex signatures and their unique regulatory challenges, including analytic performance validation, complex signature simulation, and clinical performance evaluation. We also will review the potential regulatory pathways for clearance, approval, or acceptance of complex signatures by the FDA. These regulatory pathways include regulations applicable to diagnostic devices, including companion diagnostic devices, the potential for labeling as a complementary diagnostic, and the biomarker qualification program. . As technologies evolve, and diagnostics move from detection of single biomarkers toward complex signatures, an increase in the clinical use and regulatory submission of complex signatures is anticipated. However, to date, no complex signatures have been approved as companion diagnostics. In this article, we will describe the potential benefit of complex signatures and their unique regulatory challenges including analytical performance validation, complex signature simulation, and clinical performance evaluation. We also will review the potential regulatory pathways for clearance, approval, or acceptance of complex signatures by the U.S. Food and Drug Administration (FDA). These regulatory pathways include regulations applicable to in vitro diagnostic devices, including companion diagnostic devices, the potential for labeling as a complementary diagnostic, and the biomarker qualification program. As technologies evolve, and diagnostics move from detection of single biomarkers toward complex signatures, an increase in the clinical use and regulatory submission of complex signatures is anticipated. However, to date, no complex signatures have been approved as companion diagnostics. In this article, we will describe the potential benefit of complex signatures and their unique regulatory challenges, including analytic performance validation, complex signature simulation, and clinical performance evaluation. We also will review the potential regulatory pathways for clearance, approval, or acceptance of complex signatures by the FDA. These regulatory pathways include regulations applicable to in vitro diagnostic devices, including companion diagnostic devices, the potential for labeling as a complementary diagnostic, and the biomarker qualification program. Clin Cancer Res; 23(6); 1368-72. copyright 2016 AACR. As technologies evolve, and diagnostics move from detection of single biomarkers toward complex signatures, an increase in the clinical use and regulatory submission of complex signatures is anticipated. However, to date, no complex signatures have been approved as companion diagnostics. In this article, we will describe the potential benefit of complex signatures and their unique regulatory challenges, including analytic performance validation, complex signature simulation, and clinical performance evaluation. We also will review the potential regulatory pathways for clearance, approval, or acceptance of complex signatures by the FDA. These regulatory pathways include regulations applicable to in vitro diagnostic devices, including companion diagnostic devices, the potential for labeling as a complementary diagnostic, and the biomarker qualification program. Clin Cancer Res; 23(6); 1368–72. ©2016 AACR. |
| Author | Philip, Reena Kim, Geoffrey McKee, Amy E. Beaver, Julia A. Tzou, Abraham Pazdur, Richard Blumenthal, Gideon M. |
| Author_xml | – sequence: 1 givenname: Julia A. surname: Beaver fullname: Beaver, Julia A. – sequence: 2 givenname: Abraham surname: Tzou fullname: Tzou, Abraham – sequence: 3 givenname: Gideon M. surname: Blumenthal fullname: Blumenthal, Gideon M. – sequence: 4 givenname: Amy E. surname: McKee fullname: McKee, Amy E. – sequence: 5 givenname: Geoffrey surname: Kim fullname: Kim, Geoffrey – sequence: 6 givenname: Richard surname: Pazdur fullname: Pazdur, Richard – sequence: 7 givenname: Reena surname: Philip fullname: Philip, Reena |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/27993967$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl1rFDEUhgep2A_9CUrAm95MzZlMkgmCsIxWCwVLXa9DJntmN2V2Mk0yxf57s7Yr2gvxKuHkec9HzntcHIx-xKJ4DfQMgDfvgMqmpDWrztr2ugRRAlXNs-IIOJclqwQ_yPc9c1gcx3hDKdRA6xfFYSWVYkrIo-J2MZLzjwtyhSFOaJO7Q-JHkjZIrnE9Dyb5cE8uttPgrEnOj5H4nrQ-B_AH-ebWo0lzwEiSJ1cBV86mLIxTBnEXW5qwxoQrstxgMJPD-LJ43psh4qvH86T4fv5p2X4pL79-vmgXl6XlrEllRzmoqrZVb6TJrYKSwC0qySoAqZiQnForayGt6GjHUK0E65DXPRjW2YadFB8e8k5zt8WVxTEFM-gpuK0J99obp_9-Gd1Gr_2d5ozXqq5zgtPHBMHfzhiT3rpocRjMiH6OGpoGpADRyP9AOVSKq0Zl9O0T9MbPYcw_oUE1rM5DA83Umz-b_931fnEZeP8A2OBjDNhr69KvBeVZ3KCB6p1N9M4CemcBnW2iQeidTbKaP1HvC_xb9xPdSMCM |
| CitedBy_id | crossref_primary_10_1186_s13045_017_0479_y crossref_primary_10_1080_14737159_2019_1611426 crossref_primary_10_1080_14737159_2021_1920396 crossref_primary_10_2174_1389450119666180911093143 crossref_primary_10_1002_cpt_955 crossref_primary_10_1080_14737159_2020_1728256 crossref_primary_10_1080_24709360_2021_1913706 crossref_primary_10_1200_JCO_21_02285 crossref_primary_10_1371_journal_pone_0283001 crossref_primary_10_1208_s12248_021_00574_0 crossref_primary_10_1007_s00259_018_3967_6 crossref_primary_10_1038_s41568_024_00705_7 crossref_primary_10_1016_j_arthro_2021_03_050 crossref_primary_10_1186_s13045_017_0541_9 crossref_primary_10_1634_theoncologist_2019_0054 crossref_primary_10_5306_wjco_v15_i1_23 crossref_primary_10_1002_ijc_34165 crossref_primary_10_3390_diagnostics14070713 crossref_primary_10_3389_fmed_2022_893028 crossref_primary_10_3390_biomedicines10102511 crossref_primary_10_1016_j_modpat_2023_100159 crossref_primary_10_1002_cpt_1041 crossref_primary_10_1080_14737159_2020_1762573 crossref_primary_10_1097_PAI_0000000000000605 |
| Cites_doi | 10.2217/pme.10.53 10.1634/theoncologist.2016-0101 |
| ContentType | Journal Article |
| Copyright | 2016 American Association for Cancer Research. Copyright American Association for Cancer Research Inc Mar 15, 2017 |
| Copyright_xml | – notice: 2016 American Association for Cancer Research. – notice: Copyright American Association for Cancer Research Inc Mar 15, 2017 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QO 7T5 7TO 7U9 8FD FR3 H94 P64 7X8 5PM |
| DOI | 10.1158/1078-0432.CCR-16-1098 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Biotechnology Research Abstracts Immunology Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Biotechnology Research Abstracts Oncogenes and Growth Factors Abstracts Technology Research Database AIDS and Cancer Research Abstracts Immunology Abstracts Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE Engineering Research Database Virology and AIDS Abstracts CrossRef |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1557-3265 |
| EndPage | 1372 |
| ExternalDocumentID | PMC5354944 27993967 10_1158_1078_0432_CCR_16_1098 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: Intramural FDA HHS grantid: FD999999 |
| GroupedDBID | --- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CITATION CS3 DIK DU5 E3Z EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO OK1 P0W P2P QTD RCR RHI RNS SJN TR2 W2D W8F WOQ YKV CGR CUY CVF ECM EIF NPM 7QO 7T5 7TO 7U9 8FD FR3 H94 P64 7X8 5PM |
| ID | FETCH-LOGICAL-c538t-b051924c2fa7a96719715ce9732117936750cc7467c6b0b3e9d63be54f1a3bc83 |
| ISSN | 1078-0432 1557-3265 |
| IngestDate | Thu Aug 21 14:01:01 EDT 2025 Thu Sep 04 23:10:24 EDT 2025 Fri Sep 05 14:44:33 EDT 2025 Sat Jul 26 02:25:05 EDT 2025 Mon Jul 21 06:01:44 EDT 2025 Thu Apr 24 23:12:46 EDT 2025 Tue Jul 01 01:30:07 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | 2016 American Association for Cancer Research. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c538t-b051924c2fa7a96719715ce9732117936750cc7467c6b0b3e9d63be54f1a3bc83 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 these authors contributed equally to this work |
| OpenAccessLink | https://clincancerres.aacrjournals.org/content/clincanres/23/6/1368.full.pdf |
| PMID | 27993967 |
| PQID | 1983419210 |
| PQPubID | 2046235 |
| PageCount | 5 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5354944 proquest_miscellaneous_1881761687 proquest_miscellaneous_1851295989 proquest_journals_1983419210 pubmed_primary_27993967 crossref_citationtrail_10_1158_1078_0432_CCR_16_1098 crossref_primary_10_1158_1078_0432_CCR_16_1098 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2017-03-15 |
| PublicationDateYYYYMMDD | 2017-03-15 |
| PublicationDate_xml | – month: 03 year: 2017 text: 2017-03-15 day: 15 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Philadelphia |
| PublicationTitle | Clinical cancer research |
| PublicationTitleAlternate | Clin Cancer Res |
| PublicationYear | 2017 |
| Publisher | American Association for Cancer Research Inc |
| Publisher_xml | – name: American Association for Cancer Research Inc |
| References | U.S. Food and Drug Administration (2022061100445944700_bib15) U.S. Food and Drug Administration (2022061100445944700_bib16) FDA-NIH Biomarker Working Group (2022061100445944700_bib2) 2016 U.S. Food and Drug Administration (2022061100445944700_bib13) U.S. Food and Drug Administration (2022061100445944700_bib14) U.S. Food and Drug Administration (2022061100445944700_bib11) 2014 U.S. Food and Drug Administration (2022061100445944700_bib22) U.S. Food and Drug Administration (2022061100445944700_bib20) U.S. Food and Drug Administration (2022061100445944700_bib10) U.S. Food and Drug Administration (2022061100445944700_bib21) Kazandjian (2022061100445944700_bib12) 2016; 21 Težak (2022061100445944700_bib1) 2010; 7 U.S. Food and Drug Administration (2022061100445944700_bib7) U.S. Food and Drug Administration (2022061100445944700_bib6) U.S. Food and Drug Administration (2022061100445944700_bib9) U.S. Food and Drug Administration (2022061100445944700_bib8) U.S. Food and Drug Administration (2022061100445944700_bib3) U.S. Food and Drug Administration (2022061100445944700_bib19) U.S. Food and Drug Administration (2022061100445944700_bib5) U.S. Food and Drug Administration (2022061100445944700_bib17) U.S. Food and Drug Administration (2022061100445944700_bib4) U.S. Food and Drug Administration (2022061100445944700_bib18) |
| References_xml | – ident: 2022061100445944700_bib16 article-title: CDER Medical Review(s)/Statistical Review(s) BLA 761034 Atezolizumab [Internet] – year: 2016 ident: 2022061100445944700_bib2 article-title: BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet] – ident: 2022061100445944700_bib4 article-title: FDA Premarket Approval (PMA) [Internet] – ident: 2022061100445944700_bib13 article-title: FDA PD-L1 IHC 28-8 pharmDx Summary of Safety and Effectiveness Data [Internet] – ident: 2022061100445944700_bib8 article-title: FDA 510(k) Substantial Equivalence Determination OVA1™ Decision Summary [Internet] – volume: 7 start-page: 517 year: 2010 ident: 2022061100445944700_bib1 article-title: US FDA and personalized medicine: in vitro diagnostic regulatory perspective publication-title: Personalized Med doi: 10.2217/pme.10.53 – year: 2014 ident: 2022061100445944700_bib11 article-title: In Vitro Companion Diagnostic Devices Guidance for Industry and FDA Staff [Internet] – ident: 2022061100445944700_bib18 article-title: FDA Qualification Process for Drug Development Tools: Guidance for Industry and FDA Staff [Internet] – ident: 2022061100445944700_bib21 article-title: Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Ovarian Adnexal Mass Assessment Score Test System [Internet] – ident: 2022061100445944700_bib19 article-title: FDA Biomarker Qualification Program [Internet] – ident: 2022061100445944700_bib10 article-title: Information Sheet Guidance for IRBs, Clinical Investigators, and Sponsors: Significant Risk and Nonsignificant Risk Medical Device Studies [Internet] – volume: 21 start-page: 974 year: 2016 ident: 2022061100445944700_bib12 article-title: Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer publication-title: Oncologist doi: 10.1634/theoncologist.2016-0101 – ident: 2022061100445944700_bib15 article-title: FDA VENTANA PD-L1 (SP142) Assay Summary of Safety and Effectiveness Data [Internet] – ident: 2022061100445944700_bib3 article-title: FDA Overview of IVD Regulation [Internet] – ident: 2022061100445944700_bib22 article-title: Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Gene Expression Profiling Test System for Breast Cancer Prognosis [Internet] – ident: 2022061100445944700_bib6 article-title: Evaluation of Automatic Class III Designation (De Novo) Summaries [Internet] – ident: 2022061100445944700_bib14 article-title: FDA PD-L1 IHC 28-8 pharmDx Summary of Safety and Effectiveness Data [Internet] – ident: 2022061100445944700_bib20 article-title: Critical Path Innovation Meeting [Internet] – ident: 2022061100445944700_bib7 article-title: FDA Cologuard™ Summary of Safety and Effectiveness Data [Internet] – ident: 2022061100445944700_bib9 article-title: FDA Prosigna™ Decision Summary [Internet] – ident: 2022061100445944700_bib5 article-title: Premarket Notification 510(k) [Internet] – ident: 2022061100445944700_bib17 article-title: Atezolizumab BLA 761041 Drug Label [Internet] |
| SSID | ssj0014104 |
| Score | 2.3806005 |
| SecondaryResourceType | review_article |
| Snippet | As technologies evolve, and diagnostics move from detection of single biomarkers toward complex signatures, an increase in the clinical use and regulatory... |
| SourceID | pubmedcentral proquest pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 1368 |
| SubjectTerms | Biomarkers Biomarkers, Tumor - genetics Cancer Diagnostic systems Diagnostic Test Approval Drug Discovery Humans Neoplasms - diagnosis Neoplasms - genetics Neoplasms - pathology Performance evaluation Precision Medicine Signal Transduction - genetics United States United States Food and Drug Administration |
| Title | An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/27993967 https://www.proquest.com/docview/1983419210 https://www.proquest.com/docview/1851295989 https://www.proquest.com/docview/1881761687 https://pubmed.ncbi.nlm.nih.gov/PMC5354944 |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zj9MwELbKIiFeEPcWFmQk3qqUHE7sPIayZYHdBUFW6lsUpw5bCRIoqQT71_hzzNjOUXa1HC9R5TiX5-uMx_5mhpCnuLVXRKVwVBkph8VCOmiGHRHmPsd84G6JO7pHx9HBCXu9CBej0c8Ba2nTyGlxdmFcyf9IFdpArhgl-w-S7W4KDfAb5AtHkDAc_0rGSTWZv0g0i90GTNq1fxg1XWIeN9BfDTnjSL5AErn6Pvmw-miyeuocD-_WuGODFGXNmdUFNVLNEocZaaqDtFq6YZvXoI2pLBA464lNG9QtLz9XuWWHYgx23i-apmf1ZpJIHaLddUYdWTWnuan3tVoq-JABweCN4Qsln3_Y0Am7UAHGD1lvYQ-tdgdqgDtNpZyZt2yZhtsEUPBOhYNpA429sko6BMXomxoTrRY3UcsWrUOV7AWmbo81715gSgWdNx2h0KsY9nnT2ey940VgpmLR28qWH3D8NpufHB5m6f4ivUKu-pxrjsDLRccvQv4sM4RXc0MbPgaPeXbhQ7YnRue8nd9Ju4NZUHqT3LDuC00MFm-Rkapuk2tHlqBxh3xNKgqQpANI0rqiAEnaQ5IOIUnrklpI0h6StKmphSRtIYltLSRpB8m75GS-n84OHFvVwynAuDaORKfBZ4Vf5jyPI-7F3AsLhVmjMD1hAB6sWxRYBaeIpCsDFS-jQKqQlV4eyEIE98hOVVdql9BcuJGrSsai3GeSx5L7pa8keOQq8JduOCasHdKssCnvsfLKp0y7vqHIUBIZSiIDSWRehIQMMSbT7rIvJufLny7Ya-WVWfXwLfNigbkSfc8dkyfdaVDeuCOXV6reQB-B821QifFlfYTHIy8SfEzuGwh0b-VzcC9gDMeEb4Gj64DJ47fPVKtTnUQ-DEIWM_bg8ld_SK73f-U9stOsN-oRzMIb-Vij_RfE-9w4 |
| linkProvider | Geneva Foundation for Medical Education and Research |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+FDA+Perspective+on+the+Regulatory+Implications+of+Complex+Signatures+to+Predict+Response+to+Targeted+Therapies&rft.jtitle=Clinical+cancer+research&rft.au=Beaver%2C+Julia+A&rft.au=Tzou+Abraham&rft.au=Blumenthal%2C+Gideon+M&rft.au=McKee%2C+Amy+E&rft.date=2017-03-15&rft.pub=American+Association+for+Cancer+Research+Inc&rft.issn=1078-0432&rft.eissn=1557-3265&rft.volume=23&rft.issue=6&rft.spage=1368&rft.epage=1372&rft_id=info:doi/10.1158%2F1078-0432.CCR-16-1098&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1078-0432&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1078-0432&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1078-0432&client=summon |